ResultsIQ

ResultsIQ › Latest results › Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited strategy deck summary

NSE: TORNTPHARM · BSE: 500420

Strategy deck of 30 Jun 2025, summarised by AI from the filing.

Torrent to acquire 46.39% of JB Pharma for ₹11,917 cr and merge, with scheme implementation in 15-18 months subject to approvals.

Key takeaways

  1. Acquisition Torrent acquires 46.39% of JB Pharma for ₹11,917 cr (₹1,600 per share), triggering open offer for up to 26% at ₹1,639.18 per share.
  2. Timeline Implementation of scheme of amalgamation expected in 15-18 months, subject to approvals.
  3. Approvals Transaction requires CCI, SEBI, stock exchange, shareholder, creditor and NCD holder approvals.

Original filing on BSE

Torrent Pharmaceuticals Limited Q1 FY27 results

As filed: Revenue ₹4,921 cr (+55% year on year), EBITDA ₹1,664 cr (+61% year on year), PAT ₹566 cr (+3% year on year), EBITDA margin 33.8% (+134 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹4,197 cr (+42% year on year), EBITDA ₹1,356 cr (+41% year on year), PAT ₹364 cr (−14% year on year), EBITDA margin 32.3% (−27 bps). Score 64 of 100, In line with trend. Revenue and EBITDA growth were well above the company's own trend; profit before exceptional items growth was well below it. EBITDA margin fell 27 bps year on year. Profit fell 28% from last quarter. Share price after the results: −1.3% in 28 days (Nifty 500: +2.2%).
  • Q3 FY26: Revenue ₹3,303 cr (+18% year on year), EBITDA ₹1,088 cr (+19% year on year), PAT ₹635 cr (+26% year on year), EBITDA margin 32.9% (+40 bps). Score 74 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA growth was above it; profit growth was in line with it. EBITDA margin rose 40 bps year on year. Profit lagged EBITDA because of depreciation, interest or other income, not the business. Profit rose ₹132 cr on a year ago, more than the ₹60.0 cr it added the year before. Share price after the results: +7.7% in 28 days (Nifty 500: −8.2%).
  • Q2 FY26: Revenue ₹3,302 cr (+14% year on year), EBITDA ₹1,083 cr (+15% year on year), PAT ₹591 cr (+30% year on year), EBITDA margin 32.8% (+30 bps). Score 68 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin rose 30 bps year on year. Profit rose ₹138 cr on a year ago, more than the ₹67.0 cr it added the year before. Share price after the results: +5.8% in 28 days (Nifty 500: +1.3%).
  • Q1 FY26: Revenue ₹3,178 cr (+11% year on year), EBITDA ₹1,032 cr (+14% year on year), PAT ₹548 cr (+20% year on year), EBITDA margin 32.5% (+85 bps). Score 56 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it; profit growth was below it. EBITDA margin rose 85 bps year on year. Profit lagged EBITDA because of depreciation, interest or other income, not the business. Profit rose ₹91.0 cr on a year ago, more than the ₹79.0 cr it added the year before. Share price after the results: −0.5% in 29 days (Nifty 500: −0.3%).
  • Q4 FY25: Revenue ₹2,959 cr (+8% year on year), EBITDA ₹964 cr (+9% year on year), PAT ₹498 cr (+11% year on year), EBITDA margin 32.6% (+41 bps). Score 33 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA growth was below it; profit growth was well below it. EBITDA margin rose 41 bps year on year. Share price after the results: −2.4% in 30 days (Nifty 500: +0.8%).
  • Q3 FY25: Revenue ₹2,809 cr (+3% year on year), EBITDA ₹914 cr (+5% year on year), PAT ₹503 cr (+14% year on year), EBITDA margin 32.5% (+73 bps). Score 21 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin rose 73 bps year on year.
  • Q2 FY25: Revenue ₹2,889 cr (+9% year on year), EBITDA ₹939 cr (+14% year on year), PAT ₹453 cr (+17% year on year), EBITDA margin 32.5% (+149 bps). Score 56 of 100, In line with trend. EBITDA margin rose 149 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Torrent Pharmaceuticals Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.